Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. Mylan applies one global quality standard across our facilities, and across our product line regardless of market. At Mylan, whether it’s a medication for millions or for a handful of people our priorities are to meet or exceed industry standards.

Company Growth (employees)
Type
Public
HQ
Hatfield, GB
Founded
1961
Size (employees)
35,000 (est)
Website
mylan.com
Mylan was founded in 1961 and is headquartered in Hatfield, GB

Key People at Mylan

Heather Bresch

Heather Bresch

Chief Executive Officer

Mylan Office Locations

Mylan has an office in Hatfield
Hatfield, GB (HQ)
Mosquito Way

Mylan Data and Metrics

Mylan Financial Metrics

Mylan's revenue was reported to be $7.6 b in FY, 2014 which is a 12% increase from the previous period.
USD

Revenue (FY, 2014)

7.6 b

Revenue growth (FY, 2013 - FY, 2014), %

12%

Gross profit (FY, 2014)

3.5 b

Gross profit margin (FY, 2014), %

45%

Net income (FY, 2014)

933.1 m

Market capitalization (25-Jul-2017)

20.8 b

Closing share price (25-Jul-2017)

38.8

Cash (31-May-2016)

28.7 k
Mylan's current market capitalization is $20.8 b.
USDFY, 2013FY, 2014

Revenue

6.9 b7.6 b

Revenue growth, %

12%

Cost of goods sold

3.9 b4.2 b

Gross profit

3 b3.5 b

Gross profit Margin, %

44%45%

Operating expense total

1.9 b2.2 b

Interest expense

313.3 m333.2 m

Income tax expense

120.8 m41.4 m

Net Income

626.5 m933.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

291.3 m28.9 k15.3 k28.7 k

Accounts Receivable

1.8 b9.3 k20 k12.7 k

Inventories

1.7 b1.7 b

Current Assets

4.5 b38.1 k35.3 k41.4 k

PP&E

1.7 b858.6 k856.9 k856.3 k

Goodwill

4.3 b210 k189 k189 k

Total Assets

15.2 b1.1 m1.1 m1.1 m

Accounts Payable

1.1 b656.6 k592.6 k639.3 k

Total Debt

8 b6.1 b

Current Liabilities

3 b656.6 k592.6 k639.3 k

Total Liabilities

1.1 m1.1 m1.1 m

Additional Paid-in Capital

4.1 b4.2 b

Retained Earnings

2.7 b

Total Equity

3 b1.9 k2.2 k2.2 k

Debt to Equity Ratio

2.7 x3174607.3 x

Debt to Assets Ratio

0.5 x5478.9 x

Financial Leverage

5.1 x579.4 x492.8 x484.1 x
USDFY, 2013FY, 2014

Net Income

626.5 m933.1 m

Depreciation and Amortization

516 m566.6 m

Accounts Receivable

(550 m)(940 m)

Inventories

(160 m)(150 m)

Accounts Payable

137.2 m(300 k)

Cash From Operating Activities

1.1 b1 b

Capital Expenditures

(334.6 m)(325.3 m)

Cash From Investing Activities

(1.9 b)(800.3 m)

Cash From Financing Activities

692.9 m(267.4 m)

Interest Paid

249.4 m273.8 m

Income Taxes Paid

(1.1 m)78.5 m

Free Cash Flow

1.4 b1.3 b
Y, 2016

Financial Leverage

484.1 x

Mylan Market Value History

Mylan Median Salaries

Source: 123 public H-1B filings from Mylan

Traffic Overview of Mylan

Mylan Online and Social Media Presence

Mylan News and Updates

Mylan is recalling EpiPens in the US (MYL)

Mylan is recalling EpiPens in the United States. The voluntary recall comes just 10 days after Mylan issued a recall of more than 80,000 devices from around the world. "This recall is being conducted as a result of the receipt of two previously disclosed reports outside of …

Mylan launches cheaper version of EpiPen allergy treatment

Drugmaker Mylan has started selling a generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew national scorn and attracted congressional inquiries.  The launch of Mylan's long-promised generic alternative is expected to still gene…

Mylan Will Start Selling Its Generic EpiPen at a Major Discount

The generic will be available in pharmacies starting next week

20 States Are Suing Mylan and Other Drug Companies for Allegedly Fixing Prices

"Heritage, Mylan, and Mayne knowingly agreed to allocate and divide the market," said the DOJ.

Mylan’s CEO Is Right—Pharma’s Price Hikes Could Ultimately Lead to Some Good

From within or without, change may actually be coming.

EpiPen maker Mylan is on an apology tour, we saw it, and it's not going well

Mylan CEO Heather Bresch took the stage on Thursday, ready for a confrontation.  Chief executive for the now-infamous pharmaceutical company that hiked the price of the EpiPen—that ubiquitous device so many children (and plenty of adults) depend on in the event of a life-threatening allergic rea…
Show more

Mylan Company Life and Culture

You may also be interested in